» Authors » Mina S Ally

Mina S Ally

Explore the profile of Mina S Ally including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 18
Citations 411
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Eng V, David S, Li S, Ally M, Stefanick M, Tang J
BMJ Open . 2020 Aug; 10(8):e037945. PMID: 32796021
Objective: To assess the dose-dependent relationship between smoking history and cancer screening rates or staging of cancer diagnoses. Design: Prospective, population-based cohort study. Setting: Questionnaire responses from the Women's Health...
2.
Ally M, Swetter S, Hirotsu K, Gordon J, Kim D, Wysong A, et al.
J Am Acad Dermatol . 2017 Oct; 78(2):289-292.e2. PMID: 28993006
Background: Student-athletes (SAs) have an increased skin cancer risk on account of significant ultraviolet exposure; however, their sun-protective practices are suboptimal. A novel program, Stanford University Network for Sun Protection,...
3.
Cho H, Sheu S, Kuo K, Ally M, Bailey E, Kim J, et al.
Acta Haematol . 2017 Jul; 138(1):33-38. PMID: 28668948
Background/aims: This study examined the role of random normal skin biopsy in the diagnosis of intravascular lymphoma (IVL) in adult Western patients with clinically diagnosed hemophagocytic lymphohistiocytosis (HLH). Methods: In...
4.
Solis D, Kwon G, Ransohoff K, Li S, Chahal H, Ally M, et al.
JAMA Dermatol . 2016 Dec; 153(2):189-192. PMID: 27902821
Importance: Patients with basal cell nevus syndrome (BCNS) have a greater risk of developing numerous basal cell carcinomas (BCCs). Risk factors influencing the wide variation in tumor burden are poorly...
5.
Tang J, Ally M, Chanana A, Mackay-Wiggan J, Aszterbaum M, Lindgren J, et al.
Lancet Oncol . 2016 Nov; 17(12):1720-1731. PMID: 27838224
Background: Aberrant hedgehog signalling underlies the development of basal-cell carcinomas. We previously reported the interim analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial in patients with the basal-cell...
6.
Ransohoff K, Ally M, Stefanick M, Keiser E, Spaunhurst K, Kapphahn K, et al.
Cancer Causes Control . 2016 May; 27(6):817-23. PMID: 27153844
Background: Sun exposure is a major risk factor for skin cancer; however, the relative contribution of ultraviolet (UV) exposure during childhood versus adulthood on skin cancer risk remains unclear. Objective:...
7.
Ally M, Ransohoff K, Sarin K, Atwood S, Rezaee M, Bailey-Healy I, et al.
JAMA Dermatol . 2016 Jan; 152(4):452-6. PMID: 26765315
Importance: Tumor resistance is an emerging problem for Smoothened (SMO) inhibitor-treated metastatic basal cell carcinoma (BCC). Arsenic trioxide and itraconazole antagonize the hedgehog (HH) pathway at sites distinct from those...
8.
Ally M, Tang J, Lindgren J, Acosta-Raphael M, Rezaee M, Chanana A, et al.
JAMA Dermatol . 2015 Jul; 151(10):1132-4. PMID: 26200175
No abstract available.
9.
Atwood S, Sarin K, Whitson R, Li J, Kim G, Rezaee M, et al.
Cancer Cell . 2015 Mar; 27(3):342-53. PMID: 25759020
Advanced basal cell carcinomas (BCCs) frequently acquire resistance to Smoothened (SMO) inhibitors through unknown mechanisms. Here we identify SMO mutations in 50% (22 of 44) of resistant BCCs and show...
10.
Wysong A, Ally M, Gamba C, Desai M, Swetter S, Seiffert-Sinha K, et al.
Prev Med . 2014 Aug; 69:8-12. PMID: 25150382
Objective: Evidence for the effect of non-steroidal anti-inflammatory drugs (NSAIDs) on non-melanoma skin cancer (NMSC) risk is inconsistent. We prospectively examined whether regular, inconsistent, or no/low-use of NSAIDs is associated...